Tauklarify (florquinitau F 18) is a brain PET tracer that shows tau tangles, twisted protein deposits tied to Alzheimer's. Blood tests measure a related Alzheimer's signal in blood, so new memory symptoms call for clinical review rather than headline conclusions. The FDA approval notice lists Tauklarify as approved Aug.
13, 2026 for brain PET to identify tau tangle pathology. That FDA use is for adults with cognitive impairment evaluated for Alzheimer's. In this setting, PET means a scan that uses a radioactive tracer to image brain deposits.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Does Each Test Measure?
- Why Does No Single Result Confirm Alzheimer's?
- Who Are These Tests Intended For?
- What Should You Do After New Symptoms?
What Does Each Test Measure?
Lantheus says Tauklarify is a tau PET radiodiagnostic that complements amyloid PET. Amyloid PET tracers stick to amyloid plaques, while blood tests measure phosphorylated tau, called p-tau, as an indirect blood signal, according to USC researchers.
Plaques are amyloid clumps in the brain, while p-tau is tau carrying an extra phosphate tag. A tau scan therefore asks where tangles appear in the brain, while a blood test asks whether an indirect signal warrants closer workup. That difference keeps the two tests from substituting for each other in a new-symptom visit.
Why Does No Single Result Confirm Alzheimer's?
A Reuters report on the approval notes a positive Tauklarify scan does not confirm tau pathology alone and a negative scan does not rule it out. The same report says results must be read alongside clinical evaluation.
Lantheus also states safety and effectiveness are not established for non-Alzheimer's tauopathies, diseases with tau from other causes. A positive scan in a person with recent forgetfulness still needs history, exam, and review of other contributors before any Alzheimer's conclusion. A negative scan likewise does not erase new symptoms or end follow-up.
Who Are These Tests Intended For?
The FDA clearance announcement describes Lumipulse as the first blood test cleared May 16, 2025 to aid Alzheimer's diagnosis. That FDA clearance was for adults 55 and older with signs and symptoms of disease. VA-News/AL Leader reports four FDA-cleared blood tests by August 2026, with PrecivityAD2 first indicated for symptomatic adults 40 and older.
The Alzheimer's Association guideline, summarized by Healio, applies only to cognitively impaired patients seen in specialty care, not to screening without symptoms. Research from the American Academy of Neurology, via ScienceDaily, linked impaired kidney function to higher blood markers without higher overall dementia risk. The finding came from 2,279 adults followed about eight years.
What Should You Do After New Symptoms?
Write down when forgetfulness started, how often it occurs, and what tasks it disrupts. Bring prescriptions, kidney history, and prior brain scans or spinal-fluid results if you have them.
Ask the specialist which test, if any, fits your situation. If symptoms persist or worsen, return promptly rather than waiting for a scheduled scan or repeat blood draw. Leave with a written plan for follow-up testing, symptom tracking, and when to return sooner.
- Ask whether your evaluation is happening in specialty care for cognitive impairment.
- Ask what a positive or negative result would change in your care plan.
- Ask how kidney function could affect blood-marker interpretation.
- Ask why the doctor suggests tau imaging, amyloid imaging, or blood testing for you.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
